Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice

A cyclin-dependent kinase 4/6 inhibitor combined with endocrine therapy is the standard of care for patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2−) metastatic breast cancer (mBC), but real-world effectiveness data for patients with lung or liver metastase...

Full description

Bibliographic Details
Main Authors: Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Cancers
Subjects:
metastatic breast cancer
palbociclib
liver metastasis
lung metastasis
visceral metastases
Online Access:https://www.mdpi.com/2072-6694/15/21/5268

Internet

https://www.mdpi.com/2072-6694/15/21/5268

Similar Items